Serum lnc34a is a Potential Prediction Biomarker for Bone Metastasis in Hepatocellular Carcinoma Patients
Background
Early screening and intervention therapies are crucial to improve the prognosis of hepatocellular carcinoma (HCC) patients with bone metastasis. We aimed to identify serum lncRNA as a prediction biomarker in HCC bone metastasis.
Methods
The expression levels of lnc34a in serum samples from 157 HCC patients were detected by quantitative real-time PCR. Univariate analysis and multivariate analysis were performed to determine statistically significant variables.
Results
Expression levels of lnc34a in serum from HCC patients with bone metastasis were significantly higher than those without bone metastasis. And high expression of lnc34a, vascular invasion and BCLC stage were associated with bone metastasis by analysis. Moreover, lnc34a expression was specifically associated with bone metastasis rather than lung or lymph node metastasis in HCC.
Conclusions
High serum lnc34a expression was a independent risk factor for developing bone metastasis in HCC.
Figure 1
Posted 17 Sep, 2020
On 10 Nov, 2020
Received 06 Nov, 2020
Received 24 Oct, 2020
On 16 Oct, 2020
Received 28 Sep, 2020
On 28 Sep, 2020
Received 28 Sep, 2020
On 17 Sep, 2020
On 17 Sep, 2020
On 17 Sep, 2020
Received 17 Sep, 2020
Invitations sent on 16 Sep, 2020
On 04 Sep, 2020
On 03 Sep, 2020
On 03 Sep, 2020
On 02 Sep, 2020
Serum lnc34a is a Potential Prediction Biomarker for Bone Metastasis in Hepatocellular Carcinoma Patients
Posted 17 Sep, 2020
On 10 Nov, 2020
Received 06 Nov, 2020
Received 24 Oct, 2020
On 16 Oct, 2020
Received 28 Sep, 2020
On 28 Sep, 2020
Received 28 Sep, 2020
On 17 Sep, 2020
On 17 Sep, 2020
On 17 Sep, 2020
Received 17 Sep, 2020
Invitations sent on 16 Sep, 2020
On 04 Sep, 2020
On 03 Sep, 2020
On 03 Sep, 2020
On 02 Sep, 2020
Background
Early screening and intervention therapies are crucial to improve the prognosis of hepatocellular carcinoma (HCC) patients with bone metastasis. We aimed to identify serum lncRNA as a prediction biomarker in HCC bone metastasis.
Methods
The expression levels of lnc34a in serum samples from 157 HCC patients were detected by quantitative real-time PCR. Univariate analysis and multivariate analysis were performed to determine statistically significant variables.
Results
Expression levels of lnc34a in serum from HCC patients with bone metastasis were significantly higher than those without bone metastasis. And high expression of lnc34a, vascular invasion and BCLC stage were associated with bone metastasis by analysis. Moreover, lnc34a expression was specifically associated with bone metastasis rather than lung or lymph node metastasis in HCC.
Conclusions
High serum lnc34a expression was a independent risk factor for developing bone metastasis in HCC.
Figure 1